Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,919Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-36.4EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)21.9Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %2.2PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M12,900,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IYH

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

IYH is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


IYH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Keogh, WillemSenior Officer 2016-09-08Buy338$21.28608.08view
Sardo, Vincent JamesDirector 2016-09-08Sell1,500$43.05250.01view
Larson, Douglas RobertDirector, Senior Officer 2016-09-08Sell800$8.351704.55view
Fraser, AlisonDirector or Senior Officer of Insider or Subsidiar 2016-09-08Sell12,700$10.181380.16view
Brown, ArthurDirector 2016-09-08Sell250,000$0.07215157.14view
Brewster, NormanSenior Officer 2016-09-08Sell45,000$0.03502166.67view
Darling, Neil B.T.Director 2016-09-08Buy53,500$0.2755707.41view
Porter, Brian JDirector, Senior Officer 2016-09-08Sell25,176$70.17114.74view
Marsh, John M.Director 2016-09-08Sell36,000$29.5410.78view
Graham, Eric JohnSenior Officer 2016-09-08Buy1,700$3.234565.02view

Quarterly/Annual Reports about IYH:

    News about IYH:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Will Sales of Xeljanz Offset Falling Sales of Enbrel? Sep 05 2016
    How Pfizer Plans to Extend Ibrance beyond Breast Cancer Treatment Sep 02 2016
    A Look at the Drugs That Are Driving Eli Lilly’s Revenues Sep 01 2016
    Why Pfizer’s Valuation Is Suffering Aug 31 2016
    Ibrance and Xtandi Could Be in the Top 10 Oncology Drugs by 2021 Aug 29 2016
    AbbVie Launched Zinbryta in the US in August Aug 25 2016
    Is Eli Lilly Rebounding from Patent Expiry of Cymbalta? Aug 01 2016
    3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings Jul 21 2016
    Despite Swings, Stock ETF Outlook Still Looks Strong Jul 07 2016
    How Healthcare ETFs Could Really Get it Together Jun 24 2016
    These Sector ETFs Could Lead the Market Higher Jun 09 2016
    Carl Icahn Just Bought Shares of Allergan -- Should You? Jun 01 2016
    A Healthy Assessment of Healthcare ETFs Jun 01 2016
    Health Care ETFs Outpacing Market May 26 2016
    Healthcare ETFs Could Be Second Half Rebound Ideas May 24 2016
    ETF TMI: Latest ETF Launches, Transitions & Jumps May 20 2016
    Pfizer Purchases Anacor in a $5.2 Billion Cash Deal May 18 2016
    The Last Week of April Wasn’t Good for Biotechnology Stocks May 02 2016
    What Drove Eli Lilly’s 1Q16 Earnings Growth? Apr 28 2016
    17 Healthcare ETFs Investors Should Check Up On Apr 28 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)